BCTOP-T-N01NCT05999149
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion date changed from estimate of Aug 30, 2025 to May 30, 2026
- Eligibility criteria expanded, about 2 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Start date changed from estimate of Sep 1, 2023 to Aug 20, 2023
- Study title revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Pathological complete response (pCR) rate
Timeframe: Up to approximately 24 weeks
Secondary (5)
Event-free Survival (EFS) as assessed by Investigator
Disease-free Survival (DFS) as assessed by Investigator
Distant Disease-free Survival (DDFS) as assessed by Investigator
Objective response rate (ORR) in accordance with RECIST v1.1
Number of responders Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) for target lesions assessed by MRI.
Arms and interventions
Arm AExperimental
Camrelizumab Plus Chemotherapy and Famitinib
Arm BActive comparator
Camrelizumab Plus Chemotherapy
Drugs: Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy
Sites
2 sites in 1 country